MARKET

CORT

CORT

Corcept Therapeutics Inc
NASDAQ
24.05
+0.09
+0.38%
Opening 09:37 02/07 EST
OPEN
23.98
PREV CLOSE
23.96
HIGH
24.21
LOW
23.89
VOLUME
19.78K
TURNOVER
441.31K
52 WEEK HIGH
30.14
52 WEEK LOW
17.19
MARKET CAP
2.59B
P/E (TTM)
24.18
1D
5D
1M
3M
1Y
5Y
Corcept Therapeutics: Korlym Overhang Appears To Be A Drag On Valuation Upside
Seeking Alpha · 01/08 08:36
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
Benzinga · 12/15/2022 12:19
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $30
Benzinga · 12/09/2022 11:09
HC Wainwright Cuts Price Target on Corcept Therapeutics to $30 From $33, Reiterates Buy Rating
HC Wainwright Cuts Price Target on Corcept Therapeutics to $30 From $33, Reiterates Buy Rating
MT Newswires · 12/09/2022 07:38
BRIEF-Corcept Therapeutics Settles Patent Litigation With Hikma Pharmaceuticals
Reuters · 12/08/2022 14:33
BRIEF-Corcept Therapeutics Provides Miricorilant Clinical Development Update
Reuters · 12/08/2022 13:18
Corcept Therapeutics Resolves Lawsuit Against Hikma, Allows Sale of Korlym Copy From October 2034
Corcept Therapeutics Resolves Lawsuit Against Hikma, Allows Sale of Korlym Copy From October 2034
MT Newswires · 12/08/2022 12:34
Insider Sell: Corcept Therapeutics
Insider Sell: Corcept Therapeutics
MT Newswires · 11/21/2022 17:33
More
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. It has marketed Korlym (mifepristone) for the treatment of patients suffering from Cushing’s syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Its cortisol activity can be modulated by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its compounds bind to GR but not the progesterone, estrogen, or androgen receptors.

Webull offers kinds of Corcept Therapeutics Incorporated stock information, including NASDAQ:CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CORT stock methods without spending real money on the virtual paper trading platform.